A 17-year-old male who had been diagnosed with ulcerative colitis was prescribed 80 mgprednisolone and 1,500 mg5-aminosalicylic acid (5-ASA) per day. Two weeks after initiating therapy, he was referred to our hospital for evaluation of chest pain and high fever. Electrocardiography (ECG) showed ST elevation in limb and precordial leads. Chest pain with high fever and ECGchanges were resolved after 5-ASAwas discontinued. Three weeks later, the administration of a low dose of 5-ASAwas associated with the immediate recurrence of pericarditis associated with chest pain, suggesting a hypersensitive reaction to 5-ASA in this patient. (Internal Medicine 40: 901-904, 2001) 
Introduction
Acute pericarditis is a syndrome caused by inflammation of the pericardium characterized by chest pain. The most commoncauses of acute pericarditis include idiopathic or viral pericarditis, uremia, bacterial infection, trauma, acute myocardial infarction, pericardiotomy associated with cardiac surgery, tuberculosis, neoplasm and drugs (1) . Acute pericarditis has also been identified in patients with inflammatory bowel diseases (IBD), in whomit may appear as an intestinal manifestation (2) (3) (4) (5) (6) (7) (8) or as an adverse reaction to therapeutic compounds (9) (10) (11) (12) (13) (14) . We describe 5-aminosalicylic acid (5-ASA) induced pericarditis in a 17-year-old male treated for ulcerative colitis, and discuss with the literature relative to this reaction.
Case Report
A 17-year-old male with severely active ulcerative colitis was diagnosed based upon his medical history, including findings of colonoscopy, air-contrast radiography, and histopathology. Therapy of 80 mg of prednisolone and 1,500 mg of 5-ASA per day was administered. The dosage of prednisolone was gradually reduced at a rate of 10 mgper week. Twoweeks after the initiation of the therapy, he complained of acute, severe and substernal chest pain and profound fatigue. A physical examination revealed the following: body temperature of 38.6°C, blood pressure of 120/70 mmHg,and a pulse of 1 10 beats/minute. The third heart sound was not clear and the friction rub component was not audible uponadmission. Electrocardiography (ECG) revealed ST-segment elevation in the limb and precordial leads (II, III, aVF and V^) (Fig.  1 A) . Echocardiography revealed diffuse hypokinesis of the left ventricle (LV), ejection fraction reduced by 40% and a small pericardial effusion ( Fig. 2A) . A complete blood cell count (CBC) revealed that the number of white blood cells (WBC) had increased to 18,400/|il. Blood chemistry results, namely creatine phosphokinase (CK), creatine phosphokinase-MB (CK-MB), aspartate aminotransferase (AST) and lactate dehydrogenase (LDH), were normal, whereas troponin T was slightly increased to 0. 13 ng/ml. The C-reactive protein (CRP) level was 8.7 mg/dl. At this point, 5-ASA was discontinued and prednisolone was maintained at a dose of 60 mg per day. These measures improvedhis symptoms,normalized the range of WBCand CRP, resolved the ST-segment elevation (Fig. IB) , and improved cardiac function; further pericardial effusion disappeared (Fig. 2B ). In addition to prednisolone treatment, granulocytapheresis (GCAP)therapy was implemented in place of 5-ASAonce each week using a G-l column. Overthe next three weeks, the prednisolone dose wasreduced to 30 mgper week, which did not exacerbate the symptoms of pericarditis or colitis. A trial low-dose 5-ASA of 62.5 mgwas administered according to Katsumata et al (15) because the delayed onset of initial pericarditis indicated that drug allergy remained questionable. Furthermore, pericarditis is a complication of ulcerative colitis (2) (3) (4) (5) (6) (7) (8) . After written, informed consent was obtained, a low dose 5-ASAwas given to the patient under ECGmonitoring. However, 6 hours after taking a ate allergic hypersensitive reaction to 5-ASAwith an anamnestic response to re-exposure (17) . Therefore, we postulate that pericarditis in our patient occurred because an autoimmune disease, namely ulcerative colitis caused 5-ASA induced hypersensitivity, and that the two-week delay in the initial symptoms was caused by the high dose of steroid that inadvertently abrogated the hypersensitivity. Furthermore, GCAPtherapy may have removed activated neutrophils as well as lymphocytes, thus preventing an autoimmunereaction associated with ulcerative colitis.
Because 5-ASAis effective against IBD, it was necessary to estimate its use in maintaining remission for this patient. Furthermore, because the first drug lymphocyte stimulation test (DLST)was negative, we confirmed whether or not pericarditis had been induced by 5-ASA. We therefore administered a low dose of 5-ASAto the patient after obtaining his written informed consent.
Wecould not confirm the presence of the 3rd heart sound and friction rub on admission. Although friction rub is usually audible in patients with pericarditis, frequent examination is necessary to detect it because of its evanescent nature (18) .
Systolic dysfunction was revealed by echocardiography as well as pericardial effusion, suggesting myocarditis in addition to pericarditis. However, increases in the levels of cardiac enzyme such as CK, ASTand LDHwere not evident, whereas the troponin T level was slightly increased upon admission. This may account for the myocardial involvement in this patient. In conclusion, we presented a case of pericarditis that was most likely related to the ingestion of 5-ASA. The timing of the symptomsand the recurrence with low dose 5-ASAtherapy indicate drug-hypersensitivity.
Any patient treated with 5-ASA who develops chest pain, shortness of breath, or pericardial friction rub, should be considered as having pericarditis induced by drug-hypersensitivity or as having an extra manifestation of an underlying intestinal condition. The present report found that pericarditis induced by 5-ASA is a life-threatening hypersensitive reaction that requires prompt diagnosis and immediate discontinuation of the drug.
